Abstract
Acute humoral rejection (AHR) is generally less responsive to conventional anti-rejection treatment with consequent allograft losses. Therapeutic options include antilymphocyte antibody (ATG), intravenous immunglobulin (IVIG), plasmapheresis, or immunoadsorption with protein A together with intensification of immunsuppression with a tacrolimus/mycophenolate mofetil combination. This report describes a transplant recipient who responded to rituximab therapy as treatment for steroid-, ATG-, IVIG-, and plasmapheresis-resistant AHR.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Complement C4b / analysis
-
Female
-
Graft Rejection / drug therapy*
-
Humans
-
Immunologic Factors / therapeutic use*
-
Kidney Failure, Chronic / etiology
-
Kidney Failure, Chronic / surgery*
-
Kidney Transplantation / pathology*
-
Middle Aged
-
Peptide Fragments / analysis
-
Polycystic Ovary Syndrome / complications
-
Rituximab
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Immunologic Factors
-
Peptide Fragments
-
Rituximab
-
Complement C4b
-
complement C4d